EBOS Group Ltd

EBOS Group Ltd

Health CareMedical Equipment and Services
  • Price (NZD)36.80
  • Today's Change-0.29 / -0.78%
  • Shares traded58.22k
  • 1 Year change+4.25%
  • Beta0.4437
Data delayed at least 20 minutes, as of Oct 07 2022 05:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

EBOS Group Limited is an Australasian marketer, wholesaler and distributor of healthcare, medical and pharmaceutical products. The Company is also an Australasian animal care brand owner, product marketer, and distributor. Its segments include Healthcare, Animal Care and Corporate. The Healthcare segment incorporates the sale of healthcare products in a range of sectors, such as own brands, retail healthcare, medical devices, capital equipment, pharmacy services, and wholesale activities. The Animal Care segment incorporates the sale of animal care products in a range of sectors, own brands, retail, and wholesale activities. Its Community Pharmacy business includes Symbion, Endeavour Consumer Health, ProPharma, DoseAid, TerryWhite Chemmart, and Pharmacy Wholesalers Russells, among others. Its Contract Logistics business includes Healthcare Logistics and Healthcare Logistics Clinical Trials. Its Institutional Healthcare includes Clinect, Cryomed Aesthetics and Onelink, among others.

  • Revenue in NZD (TTM)12.19bn
  • Net income in NZD230.08m
  • Incorporated1922
  • Employees3.99k
  • Location
    EBOS Group Ltd108 Wrights RoadCHRISTCHURCH 8024New ZealandNZL
  • Phone+64 33380999
  • Fax+64 33395090
  • Websitehttp://www.ebosgroup.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
(YOY change %)
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
(5 yr growth rate)
Herbalife Nutrition Ltd9.68bn601.45m3.79bn10.80k6.03--4.740.39173.303.3053.18-14.471.902.2457.42507,166.7011.8012.7018.7720.8577.6479.976.217.030.83064.392.010.004.715.2720.0211.461.09--
SUZUKEN CO., LTD.27.37bn213.18m4.16bn14.03k16.620.693812.750.152198.92198.9225,546.674,763.781.9314.744.24160,161,400.001.501.753.954.597.468.210.77990.92391.05--0.0031.844.910.975482.31-7.552.145.92
Alfresa Holdings Corporation31.65bn378.29m4.17bn11.93k11.280.71977.770.1319149.77149.7712,542.832,348.241.9516.384.25217,960,500.002.342.636.
China Medicine Health Industry Co Ltd8.85bn149.53m4.47bn8.72k29.921.69--0.50560.40250.402523.817.,087,
China National Medicines Corporation Ltd11.52bn459.61m4.67bn3.01k10.161.43--0.40512.452.4561.5017.381.7312.077.7515,440,710.007.587.3115.6316.307.738.194.373.991.70--0.12928.4815.086.0726.8612.1213.7528.47
China Medical System Holdings2.22bn791.57m5.17bn5.45k6.561.516.112.331.431.434.016.210.56714.306.721,863,021.0020.2319.2823.4521.8376.1572.5735.6734.392.94--0.123240.0720.0311.2119.2517.0123.2316.47
Jointown Pharmaceutical Group Co Ltd31.89bn391.04m5.32bn29.34k13.800.9826--0.16690.8290.82965.4312.701.478.323.774,376,941.001.953.196.319.837.598.531.332.151.032.730.588141.3510.4214.74-17.7624.343.80--
Medipal Holdings Corp40.24bn344.00m5.49bn12.80k14.610.7188.640.1364126.13126.1314,808.332,566.731.9419.674.52258,133,900.002.212.606.267.266.617.021.141.321.05--0.043626.652.481.4422.980.2824-12.037.26
McKesson Europe AG35.72bn-1.40bn7.10bn6.81k--2.19--0.1989-3.97-4.76101.589.222.7612.959.143,032,271.00-10.77-1.29-22.17-2.8710.3010.23-3.90-0.62280.89856.200.4099--8.68-14.82-2,039.29---28.840.00
EBOS Group Ltd12.19bn230.08m7.12bn3.99k28.802.7722.100.58451.311.3168.8913.582.109.988.483,053,510.003.964.456.808.2211.4911.101.881.930.774218.230.433776.5916.648.309.349.9820.347.84
China Resources Pharmaceutical Group Ltd55.85bn980.72m7.62bn62.00k7.770.673.140.13650.69330.693339.488.051.017.483.483,815,924.003.153.4012.3712.0315.2216.433.
Data as of Oct 07 2022. Currency figures normalised to EBOS Group Ltd's reporting currency: New Zealand Dollar NZD

Institutional shareholders

15.01%Per cent of shares held by top holders
HolderShares% Held
Harbour Asset Management Ltd.as of 01 Sep 20215.32m2.81%
Accident Compensation Corp.as of 16 Jul 20214.91m2.59%
The Vanguard Group, Inc.as of 09 Sep 20223.85m2.03%
Norges Bank Investment Managementas of 31 Dec 20212.88m1.52%
Guardians of New Zealand Superannuationas of 30 Jun 20212.78m1.47%
Capital Research & Management Co. (Global Investors)as of 30 Jun 20222.66m1.40%
Capital Research & Management Co. (World Investors)as of 30 Jun 20222.52m1.33%
FMR Investment Management (UK) Ltd.as of 31 Jul 20221.82m0.96%
Fidelity Management & Research Co. LLCas of 31 Jul 2022905.55k0.48%
Dimensional Fund Advisors LPas of 08 Sep 2022777.45k0.41%
More ▼
Data from 30 Jun 2021 - 21 Sep 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.